M344: Potent HDAC Inhibitor (IC50 100 nM) for Cancer and HIV-1 Research

Executive Summary: M344 is a highly potent, cell-permeable histone deacetylase (HDAC) inhibitor with an IC50 of 100 nM for HDAC enzymatic inhibition (APExBIO). It robustly induces histone acetylation and cell cycle arrest, leading to apoptosis and differentiation in cancer cell lines, including neuroblastoma and breast cancer (Brumfield et al., 2025). M344 enhances radiation sensitivity and modulates transcription factors such as NF-κB, enabling latent HIV-1 LTR gene activation (related article). The compound is soluble in DMSO and ethanol but insoluble in water, requiring careful handling for reproducible results (APExBIO). Benchmark studies confirm its superior cytostatic and cytotoxic effects relative to clinical HDAC inhibitors in preclinical neuroblastoma models (IJMS, 2025).

Biological Rationale

Histone deacetylases (HDACs) are key enzymes that remove acetyl groups from histone proteins, promoting chromatin condensation and repressing gene transcription. Aberrant HDAC activity is linked to tumorigenesis, as it can silence genes that control cell cycle arrest and apoptosis (Brumfield et al., 2025). In pediatric cancers such as neuroblastoma, HDAC expression is elevated in advanced-stage tumors. Inhibition of HDACs restores histone acetylation, leading to reactivation of tumor suppressor genes and apoptosis pathways. M344, supplied by APExBIO, is a tool compound for dissecting the HDAC pathway, enabling precision modulation of gene expression in both cancer and viral latency research (APExBIO).

Mechanism of Action of M344

M344 binds to and inhibits class I and class II HDAC enzymes with an in vitro IC50 of 100 nM (APExBIO). This inhibition increases histone acetylation, resulting in relaxed chromatin structure and enhanced transcription of genes controlling differentiation and apoptosis. In cancer cells, M344 induces G0/G1 cell cycle arrest and activates caspase-dependent apoptosis ( IJMS, 2025). In HIV-1 models, M344 modulates NF-κB activity and activates latent viral LTR gene expression, supporting its evaluation as an anti-latency agent (related article). The compound's cell permeability and robust induction of histone acetylation distinguish it from less potent HDAC inhibitors.

Evidence & Benchmarks

• M344 exhibits HDAC inhibitory activity with an IC50 of 100 nM in biochemical assays (APExBIO).
• In neuroblastoma (CH-LA 90) and medulloblastoma (D341 MED) cell lines, M344 inhibits proliferation with GI50 values of 0.63–0.65 μM (Brumfield et al., 2025).
• MCF-7 breast cancer cells demonstrate cell cycle arrest and apoptosis upon M344 treatment at submicromolar concentrations (Brumfield et al., 2025).
• M344 enhances radiotherapy response in human squamous carcinoma lines SCC-35 and SQ-20B (APExBIO).
• M344 induces histone acetylation and upregulates transcription factors such as NF-κB, promoting latent HIV-1 LTR gene activation (gap-26.com).
• In vivo, metronomic M344 dosing suppresses tumor growth and extends survival in neuroblastoma xenograft models (IJMS, 2025).
• M344 demonstrates superior cytostatic and cytotoxic effects compared to vorinostat (SAHA) in preclinical neuroblastoma assays (Brumfield et al., 2025).

Compared to previous reviews that focus on general mechanistic insights, this article provides updated, benchmarked in vitro and in vivo efficacy data and direct workflow guidance for reproducible results with M344.

Applications, Limits & Misconceptions

M344 is used extensively in cancer biology for cell proliferation, apoptosis, and differentiation assays. It is validated in neuroblastoma, medulloblastoma, and breast cancer lines for HDAC pathway and epigenetic regulation studies (IJMS, 2025). M344 is also applied in HIV-1 latency models due to its effects on NF-κB and LTR activation (gap-26.com).

For more advanced strategic perspectives, see this expert guide, which outlines translational potential and future clinical pathways; the present article expands by providing granular workflow and toxicity parameters.

Common Pitfalls or Misconceptions

• M344 is not water-soluble; improper solvent use leads to precipitation and poor bioavailability (APExBIO).
• Toxicity above 10 μM is high in most cell types; only a fraction of cells undergo differentiation at these concentrations (Brumfield et al., 2025).
• Long-term storage of solutions is not recommended; loss of potency and increased degradation risk (APExBIO).
• M344 is not a pan-cancer therapeutic: Its efficacy is context-dependent and varies across tumor types and models.
• Comparison to SAHA (vorinostat): M344 is more cytotoxic in neuroblastoma but may be less tolerable in ex vivo brain slices (IJMS, 2025).

Workflow Integration & Parameters

M344 is supplied as a solid by APExBIO (product page). Dissolve in DMSO (≥14.75 mg/mL) or ethanol (≥12.88 mg/mL, with ultrasonic assistance). Warm to 37°C and use ultrasonic shaking for optimal dissolution. Final working concentrations range from 1–100 μM, with most studies employing 0.5–10 μM for 1–7 day treatments (Brumfield et al., 2025). For cell-based assays, add M344 directly to culture medium after preparation. Monitor cell viability, apoptosis, and differentiation endpoints (e.g., annexin V, caspase activation, cell cycle analysis). Avoid storing diluted solutions; prepare fresh aliquots for each experiment. M344 is compatible with standard histone acetylation and gene expression assays. See this troubleshooting guide for advanced workflow advice; the present article clarifies toxicity thresholds and solvent parameters in more detail.

Conclusion & Outlook

M344 is a validated, potent, and cell-permeable HDAC inhibitor with broad utility in cancer and HIV-1 latency research. Its low nanomolar IC50, robust induction of apoptosis, and superior cytostatic effects in neuroblastoma position it as a benchmark compound for epigenetic modulation studies (Brumfield et al., 2025). Careful attention to solubility, dosing, and toxicity is essential for optimal results. Continued research will further define M344's translational applications in oncology and viral latency.